{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:20:18Z","timestamp":1775686818715,"version":"3.50.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"DOI":"10.1093\/jac\/dkx338","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T15:13:30Z","timestamp":1503587610000},"page":"204-211","source":"Crossref","is-referenced-by-count":14,"title":["A comparison of levofloxacin and oral third-generation cephalosporins as antibacterial prophylaxis in acute leukaemia patients during chemotherapy-induced neutropenia"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-8353","authenticated-orcid":false,"given":"Kristyn E","family":"Yemm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2146-5766","authenticated-orcid":false,"given":"Jason N","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin C","family":"Mara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross A","family":"Dierkhising","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritish K","family":"Tosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,10,11]]},"reference":[{"key":"key\n\t\t\t\t20171215014148_dkx338-B1","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B2","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.6004\/jnccn.2012.0146","article-title":"Prevention and treatment of cancer-related infections","volume":"10","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B3","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1056\/NEJMoa050078","article-title":"Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas","volume":"353","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/dkl425","article-title":"Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis","volume":"59","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B6","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/cncr.22205","article-title":"Antibiotic prophylaxis in neutropenic patients","volume":"107","year":"2006","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/QCO.0b013e32834cf054","article-title":"Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients","volume":"24","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/10428194.2010.518655","article-title":"Audit of fluoroquinolone prophylaxis against chemotherapy-induced febrile neutropenia in a hospital with highly prevalent fluoroquinolone resistance","volume":"52","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10096-005-1278-x","article-title":"Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia","volume":"24","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B10","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1086\/428732","article-title":"Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies","volume":"40","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B11","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/499406","article-title":"The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs","volume":"42","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jac\/dkh510","article-title":"Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002","volume":"55","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/cncr.24812","article-title":"Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms","volume":"116","year":"2010","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3109\/10428194.2012.736988","article-title":"Fluoroquinolone prophylaxis: worth the cost?","volume":"54","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/10428194.2010.527408","article-title":"Fluoroquinolone prophylaxis: a word of caution","volume":"52","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1445-5994.2010.02341.x","article-title":"Use of antibacterial prophylaxis for patients with neutropenia","volume":"41","year":"2011","journal-title":"Intern Med J"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF01645369","article-title":"Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil","volume":"19","year":"1991","journal-title":"Infection"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF01645370","article-title":"In vitro activity of cefpodoxime and ten other cephalosporins against gram-positive cocci, Enterobacteriaceae and Pseudomonas aeruginosa, including \u03b2-lactamase producers","volume":"19","year":"1991","journal-title":"Infection"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/BF01645371","article-title":"Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity","volume":"19","year":"1991","journal-title":"Infection"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B20","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.clinthera.2014.04.013","article-title":"Cefpodoxime for antimicrobial prophylaxis in neutropenia: a retrospective case series","volume":"36","year":"2014","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","year":"2009","journal-title":"J Biomed Inform"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B23","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1086\/428055","article-title":"Antimicrobial safety: focus on fluoroquinolones","volume":"41","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/11531490-000000000-00000","article-title":"Safety considerations of fluoroquinolones in the elderly: an update","volume":"27","year":"2010","journal-title":"Drugs Aging"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hon.783","article-title":"Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider","volume":"24","year":"2006","journal-title":"Hematol Oncol"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B26","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1200\/JCO.1998.16.3.1179","article-title":"Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B27","doi-asserted-by":"crossref","first-page":"979.","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00008","article-title":"Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients","volume":"142","year":"2005","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B28","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.ejca.2005.03.006","article-title":"Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials","volume":"41","year":"2005","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JCO.2005.03.2847","article-title":"Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/pbc.23075","article-title":"Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors","volume":"58","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B31","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1742-1241.2006.01163.x","article-title":"Retrospective analysis of bacteremia because of Enterobacter cloacae compared with Escherichia coli bacteremia","volume":"61","year":"2007","journal-title":"Int J Clin Pract"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0195-6701(92)90057-S","article-title":"Retrospective 6-year study of Enterobacter bacteraemia in a Danish university hospital","volume":"20","year":"1992","journal-title":"J Hosp Infect"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B33","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.ajic.2016.05.017","article-title":"Association between chronic hemodialysis and bloodstream infections caused by chromosomally mediated AmpC-producing Enterobacteriaceae","volume":"44","year":"2016","journal-title":"Am J Infect Control"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/sj.bmt.1703413","article-title":"Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients","volume":"29","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B35","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/jac\/dkm318","article-title":"Mortality and delay in effective therapy associated with extended-spectrum \u03b2-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis","volume":"60","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171215014148_dkx338-B36","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/cid\/ciu182","article-title":"Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia","volume":"58","year":"2014","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/1\/204\/22755585\/dkx338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T02:53:38Z","timestamp":1513306418000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/73\/1\/204\/4457940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,11]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,10,11]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx338","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2017,10,11]]}}}